Obinutuzumab in the Management of Idiopathic Membranous Nephropathy

Obinutuzumab-IMN

To observe the efficacy and safety of obinutuzumab in Chinese population with idiopathic membranous nephropathy and guide clinical management.

2023-07-01

2023-12-01

2023-12-01

Not yet recruiting

30

Inclusion Criteria: 1. Clinical diagnosis of nephrotic syndrome. 2. The diagnosis of IMN was confirmed by renal biopsy pathology (light and electron microscopy) or if the serum pla2r antibody was greater than 20 IU / ml. 3. Those who have failed glucocorticoid therapy combined with cyclophosphamide or other immunosuppressive agents or rituximab, or have recurrent relapses. 4. Treatment with inotuzumab. Exclusion Criteria: 1. Patients with positive HBV serologic markers (HBsAg or / and HBeAg), HCV positivity, or abnormal liver function tests (alt, AST, or bilirubin more than 2 times the upper limit of normal and persistently elevated for 2 weeks). 2. Patients with congenital or acquired immunodeficiency, or combined infections such as active tuberculosis, active CMV, etc. Patients with CO morbid severe infections requiring intravenous antibiotics. 3. Patients with other serious physical or psychological diseases. 4. Patients with congenital heart disease, arrhythmia, heart failure and other severe cardiovascular disease, tumor.

{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'CASE_CONTROL', 'timePerspective': 'RETROSPECTIVE'}, 'enrollmentInfo': {'count': 30, 'type': 'ESTIMATED'}}

2023-05-10